Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation.

Animals Mice Cell Line COVID-19 Immune Evasion SARS-CoV-2 / immunology Spike Glycoprotein, Coronavirus / genetics Coronavirus Nucleocapsid Proteins / genetics Virulence Virulence Factors / genetics Humans COVID-19 Vaccines / immunology Lung / cytology Virus Replication Mutation

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
03 2023
Historique:
received: 16 03 2022
accepted: 04 01 2023
pubmed: 12 1 2023
medline: 4 3 2023
entrez: 11 1 2023
Statut: ppublish

Résumé

The SARS-CoV-2 Omicron variant is more immune evasive and less virulent than other major viral variants that have so far been recognized

Identifiants

DOI: 10.1038/s41586-023-05697-2 PMID: 36630998
pubmed: 36630998
doi: 10.1038/s41586-023-05697-2
pii: 10.1038/s41586-023-05697-2
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
NSP6 protein, SARS-CoV-2 0
Coronavirus Nucleocapsid Proteins 0
Virulence Factors 0
COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-150

Subventions

Organisme : NIH HHS
ID : S10 OD026983
Pays : United States
Organisme : NIH HHS
ID : S10 OD030269
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
pubmed: 35016198 doi: 10.1038/s41586-021-04388-0
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
pubmed: 35016199 doi: 10.1038/s41586-021-04389-z
Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599–601 (2022).
pubmed: 35030645 doi: 10.1056/NEJMc2119641
Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693–699 (2022).
pubmed: 35062016 doi: 10.1038/s41586-022-04442-5
Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687–692 (2022).
pubmed: 35062015 pmcid: 8942849 doi: 10.1038/s41586-022-04441-6
Lewnard, J. A. et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat. Med. 28, 1933–1943 (2022).
pubmed: 35675841 doi: 10.1038/s41591-022-01887-z
Wolter, N. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 399, 437–446 (2022).
pubmed: 35065011 pmcid: 8769664 doi: 10.1016/S0140-6736(22)00017-4
Ulloa, A. C., Buchan, S. A., Daneman, N. & Brown, K. A. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. J. Am. Med. Assoc. 327, 1286–1288 (2022).
doi: 10.1001/jama.2022.2274
Uraki, R. et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612, 540–545 (2022).
pubmed: 36323336 doi: 10.1038/s41586-022-05482-7
Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119–127 (2022).
pubmed: 35576972 doi: 10.1038/s41586-022-04856-1
Dyer, O. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. Br. Med. J. 375, n3104 (2021).
doi: 10.1136/bmj.n3104
Sigal, A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat. Rev. Immunol. 22, 69–71 (2022).
pubmed: 35046570 pmcid: 8767774 doi: 10.1038/s41577-022-00678-4
WHO. Tracking SARS-CoV-2 variants https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2022).
Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
pubmed: 35016196 doi: 10.1038/s41586-021-04387-1
Gu, H. et al. Probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg. Infect. Dis. 28, 460–462 (2022).
pubmed: 34860154 pmcid: 8798678 doi: 10.3201/eid2802.212422
Iuliano, A. D. et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020–January 2022. Morb. Mortal. Wkly Rep. 71, 146–152 (2022).
doi: 10.15585/mmwr.mm7104e4
CDC. COVID Data Tracker https://covid.cdc.gov/covid-data-tracker/#variant-proportions (2022).
Taylor, L. Covid-19: Omicron drives weekly record high in global infections. Br. Med. J. 376, o66 (2022).
doi: 10.1136/bmj.o66
Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484 (2022).
pubmed: 35081335 pmcid: 8723827 doi: 10.1016/j.cell.2021.12.046
Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700–705 (2022).
pubmed: 35104835 pmcid: 8942852 doi: 10.1038/s41586-022-04462-1
Smyth, D. S. et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nat. Commun. 13, 635 (2022).
pubmed: 35115523 pmcid: 8813986 doi: 10.1038/s41467-022-28246-3
Kirby, A. E. et al. Notes from the field: early evidence of the SARS-CoV-2 B.1.1.529 (Omicron) variant in community wastewater—United States, November–December 2021. Morb. Mortal. Wkly Rep. 71, 103–105 (2022).
doi: 10.15585/mmwr.mm7103a5
Herrmann, A. et al. Cloning of a passage-free SARS-CoV-2 genome and mutagenesis using red recombination. Int. J. Mol. Sci. 22, 10188 (2021).
pubmed: 34638527 pmcid: 8507965 doi: 10.3390/ijms221910188
Liu, G. & Gack, M. U. An optimized circular polymerase extension reaction-based method for functional analysis of SARS-CoV-2. Preprint at https://doi.org/10.1101/2022.11.26.518005 (2022).
Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature 603, 706–714 (2022).
pubmed: 35104837 pmcid: 8942856 doi: 10.1038/s41586-022-04474-x
Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161–1179 (2022).
pubmed: 35798890 pmcid: 9352574 doi: 10.1038/s41564-022-01143-7
Martines, R. B. et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg. Infect. Dis. 26, 2005–2015 (2020).
pubmed: 32437316 pmcid: 7454055 doi: 10.3201/eid2609.202095
Huang, J. et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27, 962–973 (2020).
pubmed: 32979316 pmcid: 7500949 doi: 10.1016/j.stem.2020.09.013
Mulay, A. et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep. 35, 109055 (2021).
pubmed: 33905739 pmcid: 8043574 doi: 10.1016/j.celrep.2021.109055
Liu, S., Selvaraj, P., Sangare, K., Luan, B. & Wang, T. T. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. Cell Rep. 40, 111359 (2022).
pubmed: 36075211 pmcid: 9420700 doi: 10.1016/j.celrep.2022.111359
Carossino, M. et al. Fatal neurodissemination and SARS-CoV-2 tropism in K18-hACE2 mice is only partially dependent on hACE2 expression. Viruses 14, 535 (2022).
pubmed: 35336942 pmcid: 8955233 doi: 10.3390/v14030535
Huang, Y., Yang, C., Xu, X. F., Xu, W. & Liu, S. W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141–1149 (2020).
pubmed: 32747721 pmcid: 7396720 doi: 10.1038/s41401-020-0485-4
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
pubmed: 32225176 doi: 10.1038/s41586-020-2180-5
Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655 (2020).
pubmed: 32571838 pmcid: 7319273 doi: 10.1126/science.abc6952
Voss, W. N. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science 372, 1108–1112 (2021).
pubmed: 33947773 doi: 10.1126/science.abg5268
Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).
pubmed: 32527802 pmcid: 7292505 doi: 10.1126/sciimmunol.abc8413
Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020).
pubmed: 32454513 doi: 10.1038/s41586-020-2380-z
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042 (2020).
pubmed: 32991844 pmcid: 7494283 doi: 10.1016/j.cell.2020.09.037
Chang, M. C., Hild, S. & Grieder, F. Nonhuman primate models for SARS-CoV-2 research: consider alternatives to macaques. Lab Anim. 50, 113–114 (2021).
doi: 10.1038/s41684-021-00755-6
Kumari, P. et al. Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses 13, 132 (2021).
pubmed: 33477869 pmcid: 7832889 doi: 10.3390/v13010132
Peacock, T. P. et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein. Preprint at https://doi.org/10.1101/2021.12.31.474653 (2022).
Padmanabhan, P. & Dixit, N. M. Modelling how the altered usage of cell entry pathways by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and cathepsin B/L inhibitors. Preprint at https://doi.org/10.1101/2022.01.13.476267 (2022).
Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715–720 (2022).
pubmed: 35104836 doi: 10.1038/s41586-022-04479-6
Grau-Exposito, J. et al. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLoS Pathog. 18, e1010171 (2022).
pubmed: 35025963 pmcid: 8791477 doi: 10.1371/journal.ppat.1010171
Zhao, H. et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect. 11, 277–283 (2022).
pubmed: 34951565 pmcid: 8774049 doi: 10.1080/22221751.2021.2023329
Ricciardi, S. et al. The role of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle. Nature 606, 761–768 (2022).
pubmed: 35551511 pmcid: 7612910 doi: 10.1038/s41586-022-04835-6
Sun, X. et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 29, 1240–1254 (2022).
pubmed: 34997207 pmcid: 9177730 doi: 10.1038/s41418-021-00916-7
Cottam, E. M., Whelband, M. C. & Wileman, T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy 10, 1426–1441 (2014).
pubmed: 24991833 pmcid: 4203519 doi: 10.4161/auto.29309
Benvenuto, D. et al. Evolutionary analysis of SARS-CoV-2: how mutation of non-structural protein 6 (NSP6) could affect viral autophagy. J. Infect. 81, e24–e27 (2020).
pubmed: 32283146 pmcid: 7195303 doi: 10.1016/j.jinf.2020.03.058
Gosert, R., Kanjanahaluethai, A., Egger, D., Bienz, K. & Baker, S. C. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J. Virol 76, 3697–3708 (2002).
pubmed: 11907209 pmcid: 136101 doi: 10.1128/JVI.76.8.3697-3708.2002
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 (2021).
pubmed: 33535027 pmcid: 7839837 doi: 10.1016/j.chom.2021.01.014
Shah, M. & Woo, H. G. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved CO VID-19 therapeutic antibodies. Front. Immunol. 12, 830527 (2021).
pubmed: 35140714 doi: 10.3389/fimmu.2021.830527
Ye, G., Liu, B. & Li, F. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. Nat. Commun. 13, 1214 (2022).
pubmed: 35241675 pmcid: 8894419 doi: 10.1038/s41467-022-28882-9
Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).
pubmed: 35016197 doi: 10.1038/s41586-022-04399-5
Torii, S. et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 35, 109014 (2021).
pubmed: 33838744 pmcid: 8015404 doi: 10.1016/j.celrep.2021.109014
Chen, D. Y. et al. SARS-CoV-2 disrupts proximal elements in the JAK-STAT Pathway. J. Virol. 95, e0086221 (2021).
pubmed: 34260266 doi: 10.1128/JVI.00862-21
Tzou, P. L., Tao, K., Pond, S. L. K. & Shafer, R. W. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE 17, e0261045 (2022).
pubmed: 35263335 pmcid: 8906623 doi: 10.1371/journal.pone.0261045
Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407 (2020).
pubmed: 32669681 pmcid: 7610519 doi: 10.1038/s41564-020-0770-5
Aksamentov I, R. C., Hodcroft, E. & Neher, R. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw. 6, 3773 (2021).
doi: 10.21105/joss.03773
Jacob, A. et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat. Protoc. 14, 3303–3332 (2019).
pubmed: 31732721 pmcid: 7275645 doi: 10.1038/s41596-019-0220-0

Auteurs

Da-Yuan Chen (DY)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
ORCID: 0000-0002-1957-3330

Chue Vin Chin (CV)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.

Devin Kenney (D)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Department of Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.

Alexander H Tavares (AH)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.

Nazimuddin Khan (N)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.

Hasahn L Conway (HL)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
ORCID: 0000-0001-7328-3521

GuanQun Liu (G)

Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, USA.
ORCID: 0000-0003-2520-7625

Manish C Choudhary (MC)

Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Cambridge, MA, USA.

Hans P Gertje (HP)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.

Aoife K O'Connell (AK)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
ORCID: 0000-0001-7027-4267

Scott Adams (S)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Department of Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
ORCID: 0000-0002-1472-0223

Darrell N Kotton (DN)

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
The Pulmonary Center and Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
ORCID: 0000-0002-9604-8476

Alexandra Herrmann (A)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Armin Ensser (A)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

John H Connor (JH)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Department of Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
ORCID: 0000-0002-8867-7256

Markus Bosmann (M)

The Pulmonary Center and Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Department of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
ORCID: 0000-0003-2773-1033

Jonathan Z Li (JZ)

Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Cambridge, MA, USA.
ORCID: 0000-0001-9914-9662

Michaela U Gack (MU)

Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL, USA.
ORCID: 0000-0002-2163-2598

Susan C Baker (SC)

Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
ORCID: 0000-0001-6485-8143

Robert N Kirchdoerfer (RN)

Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, WI, USA.
ORCID: 0000-0002-5974-2709

Yachana Kataria (Y)

Department of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.

Nicholas A Crossland (NA)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Department of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
ORCID: 0000-0003-3873-9188

Florian Douam (F)

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Department of Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.

Mohsan Saeed (M)

Department of Biochemistry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. msaeed1@bu.edu.
National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA. msaeed1@bu.edu.
ORCID: 0000-0001-8505-7054

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Phénomènes biologiques › Interactions hôte-microbes › Interactions hôte-pathogène › Échappement immunitaire › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines nucléocapside › Protéines de la nucléocapside des coronavirus › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Phénomènes microbiologiques › Virulence › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Facteurs de virulence › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Appareil respiratoire › Poumon › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Spike and nsp6 are key determinants of...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Spike and nsp6 are key determinants of...